Samoylenko, V; Rahman, MM; Tekwani, BL; Tripathi, LM; Wang, Y; Khan, SI; Khan, IA; Miller, LS; Joshi, VC; Muhammad, I. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease J. Ethnopharmacol., 3 Feb 2010, 127 (2), 357–367. 357 kB. https://doi.org/10.1016/j.jep.2009.10.030 #7 MS,NMR
Glennon, RA; Dukat, M; Grella, B; Hong, S; Costantino, L; Teitler, M; Smith, C; Egan, C; Davis, K; Mattson, MV. Binding of β-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors Drug Alcohol Depend., 1 Aug 2000, 60 (2), 121–132. 276 kB. https://doi.org/10.1016/S0376-8716(99)00148-9
McKenna, DJ. Monoamine oxidsase inhibitors in Amazonian hallucinogenic plants: Ethnobotanical, phytochemical, and pharmacological investigations Ph. D. Thesis, University of British Columbia, BC, Canada, 26 Apr 1984. 12.2 MB. LC,MS,UV,TLC
McIlhenny, EH; Pipkin, KE; Standish, LJ; Wechkin, HA; Strassman, R; Barker, SA. Direct analysis of psychoactive tryptamine and harmala alkaloids in the Amazonian botanical medicine ayahuasca by liquid chromatography–electrospray ionization-tandem mass spectrometry J. Chromatogr. A, 18 Dec 2009, 1216 (51), 8960–8968. 450 kB. https://doi.org/10.1016/j.chroma.2009.10.088 LC,MS
Pires, APS; de Oliveira, CDR; Moura, S; Dõrr, FA; Silva, WAE; Yonamine, M. Gas chromatographic analysis of dimethyltryptamine and β-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage Phytochem. Anal., 1 Mar 2009, 20 (2), 149–153. 131 kB. https://doi.org/10.1002/pca.1110 MS,NMR
Brierley, DI; Davidson, C. Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment Prog. Neuro-Psychopharmacol. Biol. Psych., 3 Dec 2012, 39 (2), 263–272. 353 kB. https://doi.org/10.1016/j.pnpbp.2012.06.001
Gambelunghe, C; Aroni, K; Rossi, R; Moretti, L; Bacci, M. Identification of N,N-dimethyltryptamine and β-carbolines in psychotropic ayahuasca beverage Biomed. Chromatogr., 1 Oct 2008, 22 (10), 1056–1059. 140 kB. https://doi.org/10.1002/bmc.1023 GC,MS
McIlhenny, EH; Riba, J; Barbanoj, MJ; Strassman, R; Barker, SA. Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine Biomed. Chromatogr., 1 Sep 2011, 25 (9), 970–984. 1.0 MB. https://doi.org/10.1002/bmc.1551 #1
McIlhenny, EH; Riba, J; Barbanoj, MJ; Strassman, R; Barker, SA. Methodology for determining major constituents of ayahuasca and their metabolites in blood Biomed. Chromatogr., 1 Mar 2012, 26 (3), 301–313. 557 kB. https://doi.org/10.1002/bmc.1657 MS
Meyer, MR; Caspar, A; Brandt, SD; Maurer, HH. A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches Anal. Bioanal. Chem., 1 Jan 2014, 406 (1), 225–237. 457 kB. https://doi.org/10.1007/s00216-013-7425-9 #Harmine LC,MS
Tascón, M; Benavente, F; Vizioli, NM; Gagliardi, LG. A rapid and simple method for the determination of psychoactive alkaloids by CE-UV: application to Peganum Harmala seed infusions: Harmala Alkaloids in vegetal decoctions by CE-UV Drug Test. Anal., 1 Apr 2017, 9 (4), 596-602. 397 kB. https://doi.org/10.1002/dta.1989 #3
Wagmann, L; Brandt, SD; Kavanagh, PV; Maurer, HH; Meyer, MR. In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks Toxicol. Lett., 17 Apr 2017, 272, 84–93. 1.9 MB. https://doi.org/10.1016/j.toxlet.2017.03.007
Jacob, P; Shulgin, AT. Structure-activity relationships of the classic hallucinogens and their analogs In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 74–91. 51 kB.
Shulgin, AT. Basic Pharmacology and Effects In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 24 Apr 2003; pp 67–137. 6.3 MB.
Shulgin, AT. Psychotomimetic agents In Psychopharmacological Agents; Gordon, M, Ed., Academic Press, New York, 1 Jan 1976; Vol. 4, pp 59–146. 3.1 MB. #XXXVIII
Phipps, SM; Grundmann, O. Pharmacology and structure-activity relationship of natural products with psychoactive effects from Salvia divinorum, Mitragyna speciosa, and Ayahuasca In Stud. Nat. Prod. Chem.; , Elsevier, 1 Jan 2017; pp 1–44. 1.4 MB. https://doi.org/10.1016/B978-0-444-63930-1.00001-6 #4,13
Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry Talanta, 15 Feb 2009, 77 (4), 1245–1272. 1.2 MB. https://doi.org/10.1016/j.talanta.2008.07.062 #Harmine GC,LC,MS,UV
Tsujikawa, K; Mohri, H; Kuwayama, K; Miyaguchi, H; Iwata, YT; Gohda, A; Fukushima, S; Inoue, H; Kishi, T. Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan Forensic Sci. Int., 1 Jan 2006, 164 (2–3), 172–178. 634 kB. https://doi.org/10.1016/j.forsciint.2006.01.004 #harmine
EMCDDA. New drugs in Europe, 2007, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2008. 381 kB. #15
Hoffer, A; Osmond, H. The Hallucinogens, Academic Press, New York, . 3.9 MB. #Harmine
Cameron, LP; Olson, DE. DARK classics in chemical neuroscience: N,N-Dimethyltryptamine (DMT) ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2344–2357. 1.4 MB. https://doi.org/10.1021/acschemneuro.8b00101 #2
Blei, F; Dörner, S; Fricke, J; Baldeweg, F; Trottmann, F; Komor, A; Meyer, F; Hertweck, C; Hoffmeister, D. Simultaneous production of psilocybin and a cocktail of β-carboline monoamine oxidase inhibitors in “magic” mushrooms Chem. Eur. J., 13 Jan 2020, 26 (3), 729–734. 1.2 MB. https://doi.org/10.1002/chem.201904363 #5 LC,MS,UV,other
Lenz, C; Sherwood, A; Kargbo, R; Hoffmeister, D. Taking different roads: L‐Tryptophan as the origin of Psilocybe natural products ChemPlusChem, 1 Jan 2021, 86 (1), 28–35. 793 kB. https://doi.org/10.1002/cplu.202000581 #harmine
Cumming, P; Scheidegger, M; Dornbierer, D; Palner, M; Quednow, BB; Martin-Soelch, C. Molecular and functional imaging studies of psychedelic drug action in animals and humans Molecules, 1 Jan 2021, 26 (9), 2451. 3.5 MB. https://doi.org/10.3390/molecules26092451 #44, 48
Mesley, RJ; Evans, WH. Infrared identification of some hallucinogenic derivatives of tryptamine and amphetamine J. Pharm. Pharmacol., 1 May 1970, 22 (5), 321–332. 775 kB. https://doi.org/10.1111/j.2042-7158.1970.tb08533.x #Harmine IR
Brimblecombe, RW; Pinder, RM. Hallucinogenic agents, Wright-Scientechnica, Bristol, UK, 1 Jan 1975. 46.2 MB. #4.29
Yu, A. Indolealkylamines: Biotransformations and potential drug-drug interactions AAPS J., 1 Jun 2008, 10 (2), 242–253. 314 kB. https://doi.org/10.1208/s12248-008-9028-5 #Harmine